• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Retatrutide 2381089-83-2
98% Bifida Ferment Lysate
rhSOD (cosmetic grade)
Recombinant humanized collagen
Recombinant Humanized Small-molecule Collagen
Recombinant Humanized Small-molecule Collagen Solution

Zydus Cadila Receives FDA Approval for Cisatracurium Besylate Injection

americanpharmaceuticalreviewSeptember 07, 2020

Tag: Zydus Cadila , Cisatracurium Besylate Injection , FDA

Zydus Cadila has received final approval from the US Food and Drug Administration (FDA) to market Cisatracurium Besylate Injection USP (US RLD: Nimbex ®) in the strength of 20 mg (base)/10 mL (2 mg/mL) Multiple-Dose Vial.

Cisatracurium Besylate is a nondepolarizing skeletal neuromuscular blocker for intravenous administration. It is an adjunct to general anaesthesia to facilitate tracheal intubation in adults and in paediatric patients 1 month to 12 years of age and to provide skeletal muscle relaxation in adults during surgical procedures or during mechanical ventilation in the ICU. The drug will be manufactured at Liva plant of Cadila Healthcare Limited.

Previous:FDA Approves Additional Doses of Trulicity for Type 2 Diabetes

Next:Santhera to Obtain Worldwide Rights to Vamorolone

Related News

Xinhua Silk Road: Evaluation report highlights Seoul 120 hotline for its efficient operation

PRNewswireDecember 18, 2024

Seoul 120 hotline has contributed to efficient city operation, according to the Evaluation Report on Worldwide City Hotline Services and Governance Effectiveness (2024) released on Wednesday.

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 h

PRNewswireDecember 18, 2024

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Pr

PRNewswireDecember 18, 2024

Zydus Cadila Receives FDA Approval for Cisatracurium Besylate Injection | Pharmasources.com

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

PRNewswireDecember 19, 2024

Pharus Diagnostics LLC. (PharusDx), announced a significant step forward in the fight against pancreatic cancer. The company is announcing availability of its OncoSweep™ Pancreas Spotlight

You may like
More>>

Irinotecan (FDA)

Irinotecan (FDA)
Medroxyprogesterone Acetate(FDA)

Medroxyprogesterone Acetate(FDA)
Irinotecan Hcl trihudrate (FDA)

Irinotecan Hcl trihudrate (FDA)
Semaglutide(FDA)

Semaglutide(FDA)
lribrin Benzenesulfonate (FDA GMP)

lribrin Benzenesulfonate (FDA GMP)
Diosmin(CEP FDA GMP)

Diosmin(CEP FDA GMP)
Ivermectin (FDA)

Ivermectin (FDA)
Sirolimus (FDA)

Sirolimus (FDA)
Vecuronium Bromide(FDA)

Vecuronium Bromide(FDA)
HFHA(m-6FDAP)

HFHA(m-6FDAP)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service